Raghav Govindarajan, MD

Myasthenia gravis (MG) is an autoimmune disease leading to muscle weakness and fatigue. Medical therapy for MG has traditionally focused on treatments to alleviate symptoms, but a range of new therapies are improving outcomes.  

Dr Raghav Govindarajan, from HSHS Medical Group in O'Fallon, Illinois, reports on therapeutic advances for patients with MG presented at the American Academy of Neurology 2022 annual meeting.  

First, Dr Govindarajan discusses interim results from the ADAPT+ study, an ongoing 3-year extension of ADAPT that evaluated the long-term safety, tolerability, and efficacy of efgartigimod.  

Next, he highlights CHAMPION MG, an open-label extension trial that looked at the long-term efficacy and safety profile of ravulizumab in adults with anti-acetylcholine receptor antibody–positive generalized MG.  

Dr Govindarajan concludes by reviewing a phase 2 study on nipocalimab, a monoclonal antibody that targets the IgG binding site on FcRn with high affinity, therefore reducing serum levels of total IgG and pathogenic IgG autoantibodies — the underlying cause of MG. This study evaluated efficacy data including myasthenia gravis activities of daily living score evaluated efficacy data including myasthenia gravis activities of daily living.  

--

Raghav Govindarajan, MD, Staff neurologist, Stroke Director, HSHS Medical Group-St Elizabeth, O'Fallon, Illinois 

Serve(d) as a speaker or a member of a speakers bureau for: Alexion 

Received research grant from: Alexion 

Received income in an amount equal to or greater than $250 from: Alexion 

Myasthenia gravis (MG) is an autoimmune disease leading to muscle weakness and fatigue. Medical therapy for MG has traditionally focused on treatments to alleviate symptoms, but a range of new therapies are improving outcomes.  

Dr Raghav Govindarajan, from HSHS Medical Group in O'Fallon, Illinois, reports on therapeutic advances for patients with MG presented at the American Academy of Neurology 2022 annual meeting.  

First, Dr Govindarajan discusses interim results from the ADAPT+ study, an ongoing 3-year extension of ADAPT that evaluated the long-term safety, tolerability, and efficacy of efgartigimod.  

Next, he highlights CHAMPION MG, an open-label extension trial that looked at the long-term efficacy and safety profile of ravulizumab in adults with anti-acetylcholine receptor antibody–positive generalized MG.  

Dr Govindarajan concludes by reviewing a phase 2 study on nipocalimab, a monoclonal antibody that targets the IgG binding site on FcRn with high affinity, therefore reducing serum levels of total IgG and pathogenic IgG autoantibodies — the underlying cause of MG. This study evaluated efficacy data including myasthenia gravis activities of daily living score evaluated efficacy data including myasthenia gravis activities of daily living.  

--

Raghav Govindarajan, MD, Staff neurologist, Stroke Director, HSHS Medical Group-St Elizabeth, O'Fallon, Illinois 

Serve(d) as a speaker or a member of a speakers bureau for: Alexion 

Received research grant from: Alexion 

Received income in an amount equal to or greater than $250 from: Alexion 

Myasthenia gravis (MG) is an autoimmune disease leading to muscle weakness and fatigue. Medical therapy for MG has traditionally focused on treatments to alleviate symptoms, but a range of new therapies are improving outcomes.  

Dr Raghav Govindarajan, from HSHS Medical Group in O'Fallon, Illinois, reports on therapeutic advances for patients with MG presented at the American Academy of Neurology 2022 annual meeting.  

First, Dr Govindarajan discusses interim results from the ADAPT+ study, an ongoing 3-year extension of ADAPT that evaluated the long-term safety, tolerability, and efficacy of efgartigimod.  

Next, he highlights CHAMPION MG, an open-label extension trial that looked at the long-term efficacy and safety profile of ravulizumab in adults with anti-acetylcholine receptor antibody–positive generalized MG.  

Dr Govindarajan concludes by reviewing a phase 2 study on nipocalimab, a monoclonal antibody that targets the IgG binding site on FcRn with high affinity, therefore reducing serum levels of total IgG and pathogenic IgG autoantibodies — the underlying cause of MG. This study evaluated efficacy data including myasthenia gravis activities of daily living score evaluated efficacy data including myasthenia gravis activities of daily living.  

--

Raghav Govindarajan, MD, Staff neurologist, Stroke Director, HSHS Medical Group-St Elizabeth, O'Fallon, Illinois 

Serve(d) as a speaker or a member of a speakers bureau for: Alexion 

Received research grant from: Alexion 

Received income in an amount equal to or greater than $250 from: Alexion